Quantum computing in healthcare: real applications and prospects

Quantum computing in healthcare is the most cited use case in the entire sector, and for good reasons, since the chemistry of drugs is quantum by nature, clinical data are oceans to be analysed and healthcare logistics overflows with optimisation problems. For this very reason, however, it is also the territory where promises most often outrun the facts. This guide distinguishes carefully what molecular simulation can do today and what it will do tomorrow, where genomics and optimisation have solid foundations, and why the protection of health data, alone among them, cannot wait, closing with the concrete path for a healthcare organisation or a pharmaceutical company that wants to begin without being led by hype. For quantum computing in healthcare to produce value, the sequence of moves matters more than the enthusiasm with which they are announced.

What are the application areas in healthcare?

There are four application areas, with very different levels of maturity from one another.

• Molecular simulation for drug discovery, the area with the soundest scientific justification, direct heir of quantum simulation.
• Analysis of genomic and clinical data, where quantum machine learning is still the subject of exploratory research.
• Operational optimisation. Staff rosters, operating theatres, drug logistics, clinical trial design.
• Health data security, which is not a future application but a present obligation, tied to post-quantum cryptography.

Anyone evaluating investments in this field should always ask which of the four areas a proposal belongs to, because the payback times are radically different. Quantum computing touches healthcare over horizons that range from the today of cryptography to the future of chemistry.

How does quantum computing help drug discovery?

The principle is straightforward, because the efficacy of a drug depends on electronic interactions between molecules, quantum phenomena that classical methods approximate with growing difficulty as correlation increases. A quantum computer represents these systems natively, promising calculations of binding affinity and reaction energies that are inaccessible today. The workflow, from the molecular Hamiltonian to the variational circuit, is the one described on the page on simulation, and the pharmaceutical application is its flagship use case. On the industrial side, the large pharmaceutical companies have had active programmes for years, typically in partnership with quantum vendors, a sign of the seriousness of the trajectory, not yet of the maturity of the result.

How close is quantum drug discovery?

The most accurate answer is that it is getting closer but not in the immediate term, and it is important to say so. The molecules that can be treated today with chemical accuracy on hardware or in emulation still number only tens of orbitals, while pharmacologically interesting systems require hundreds or thousands, with error correction as a prerequisite for exact calculations. No drug on the market today was developed through a quantum advantage. The current value is a different one, and is nonetheless concrete, because it consists in validating methods and pipelines on reduced systems, integrating quantum skills into existing computational teams and building the systematic comparison with DFT (density functional theory) and classical methods, so that when the technology is ready, and the trajectory has already shown that it is on its way, the organisation will already be ahead.

What can it do for genomics and diagnostics?

Here realism must be at its maximum, because this is the area most exposed to inflated promises. Genomic and imaging data are massive classical data, and therefore inherit all the limits discussed on the page on quantum machine learning, from the data-loading problem to barren plateaus, through to the lesson of dequantisation. The sensible directions are few but growing fast, such as data of quantum origin from advanced sensing, kernel components inside hybrid pipelines and methodological research. A healthcare organisation does well to begin studying it in the field, while it does badly to promise it as a ready-made solution.

Where does optimisation act in the clinical setting?

Optimisation acts on the most everyday and underestimated terrain, because healthcare is a factory of combinatorial problems. Think of staff rostering with regulatory and skills constraints, operating theatre scheduling, the routing of drug and sample-tube logistics, bed assignment, and the design of clinical trials that maximise the information per enrolled patient. These are problems on which variational algorithms are prototyped today in emulation, with the usual methodological caveat, since classical solvers on these problems are strong and the comparison must be made against them. The immediate benefit, reported by those who experiment, is often indirect, because formulating the problem for quantum forces one to formalise it well, and this alone improves classical solutions. For a chief operating officer, optimisation is the terrain where quantum computing can be touched on everyday problems, and it is often the most natural proof of concept to start from.

Why is health data the most exposed to the quantum threat?

Health data combine the two worst possible characteristics, a very long useful life and maximum sensitivity. A medical record, a genetic profile, a psychiatric history remain confidential for the lifetime of the patient and beyond, while data intercepted and archived today, following the harvest now, decrypt later logic, will be decryptable when the hardware matures, within the confidentiality horizon. The genome adds a unique aggravating factor, because it is immutable and also concerns family members. For this reason healthcare appears at the top of every regulatory priority list for post-quantum migration, in Europe within the NIS2 framework for essential operators. Among all the topics on this page, it is the only one with a deadline already on the calendar of general managers today.

What should a healthcare organisation do today?

A healthcare organisation should do two things in parallel, with different weights. The first, urgently, is the cryptographic inventory and the post-quantum migration plan, starting from the systems that hold long-lived data, such as electronic health records, genomic archives and telemedicine. This is ordinary cybersecurity work, with standards already published and suppliers to be involved, and it requires no quantum computing expertise to get started. The second, methodically, is a knowledge watch on the computational areas, with essential training and, where a concrete optimisation or simulation problem exists, a proof of concept in emulation with a comparison baseline. The first protects, while the second prepares, and confusing them, or funding the second while ignoring the first, is the most common governance mistake in the sector when it comes to quantum computing applied to healthcare.

What should a pharmaceutical company do?

A pharmaceutical company should build the bridge between the computational chemistry it already has and the quantum skills it still lacks, because it is on that bridge that competitive advantage will be played out in the coming years.

The first step consists in identifying, within its own portfolio, the molecular systems where classical methods show documented limits, typically those with strong electron correlation, which are also the natural candidates for a future quantum advantage.

The second step is to validate quantum pipelines on reduced versions of those systems, working in emulation and always keeping the DFT baseline alongside, so that every result is measured against the best classical method available and not against a void.

The third step, perhaps the most strategic, is to train its own computational chemists on quantum tools, because that hybrid profile, combining knowledge of the pharmaceutical domain with mastery of the new methods, is today the rarest and most valuable on the quantum computing job market, and cultivating it internally costs far less than buying it tomorrow. In this direction the investment remains contained and the return is twofold, because the company will find itself with a method already proven and applicable to pharmaceutical research.

What role does emulation play in the healthcare journey?

Emulation plays the role of the protected environment in which all the preparatory work takes place without risk and without the costs of hardware access. On the EQM platform used by HumanQ it will be possible to validate molecular simulation circuits by comparing them with the known solutions, and to prototype clinical optimisation formulations by measuring how they scale.

What are the realistic timelines, in brief?

Here is a roadmap for the healthcare sector.

• Immediately. Post-quantum protection of data, because the risk is already active and the regulatory deadline is set.
• One to two years. Proofs of concept in emulation on clinical optimisation and on the simulation of reduced molecules, with team training.
• Three to five years. First expected advantages in molecular simulation on systems of real interest, conditional on progress in error correction.
• Beyond. Quantum genomics and diagnostics.

Quantum computing in healthcare is, in short, a race with a single mandatory sprint right now, and those who run the sprint and set out the course methodically will arrive sooner and in the right order.